Corrigendum to “Efficacy and Tolerability of Intravenous Ferric Carboxymaltose in Patients with Iron Deficiency at a Hospital Outpatient Clinic: A Retrospective Cohort Study of Real-World Clinical Practice”
Table 3
Odds ratio of clinical failure in primary and secondary efficacy endpoints for intravenous FCM treatment.
Hemoglobin increase ≥2 g/dL
Hemoglobin increase ≥3 g/dL
Transferrin saturation >20%
Characteristic
N
n (%)
OR (95% CI)
N
n (%)
OR (95% CI)
N
n (%)
OR (95% CI)
All
459
190 (41)
-
459
94 (20)
-
450
285 (63)
-
Male
101
35 (35)
1.7 (0.94-3.13)
101
20 (20)
1.01 (0.50-2.10)
98
54 (55)
1.45 (0.91-2.31)
Iron deficiency anemia
373
184 (49)
0.07 (0.03-0.15)
373
92 (25)
0.07 (0.01-0.22)
373
232 (62)
1.29 (0.77-2.23)
Iron deficiency without anemia
77
-
-
77
-
-
77
53 (69)
0.77 (0.45-1.30)
Diseases of the digestive system
199
79 (40)
0.88 (0.54-1.42)
199
43 (22)
0.57 (0.31-1.04)
195
123 (63)
0.95 (0.63-1.4)
Diseases of the genitourinary system
121
67 (55)
0.46 (0.25-0.87)
121
31 (26)
1.22 (0.59-2.54)
52
82 (68)
0.88 (0.52-1.48)
Neoplasms
47
12 (26)
2.19 (0.98-5.19)
47
5 (11)
1.63 (0.57-5.72)
45
30 (67)
0.70 (0.35-1.38)
Diseases of the circulatory system
38
11 (29)
3.34 (1.31-8.98)
38
6 (16)
2.1 (0.72-6.86)
38
18 (47)
1.82 (0.91-3.65)
Other diseases
54
21 (39)
0.94 (0.45-1.97)
54
9 (17)
1.12 (0.47-2.90)
52
32 (62)
1.13 (0.61-2.06)
Cumulative FCM treatment dose
500 mg
122
18 (15)
-
122
5 (4)
-
114
58 (51)
-
501–1000 mg
290
141 (49)
0.34 (0.18-0.62)
290
70 (24)
0.36 (0.12-0.92)
289
189 (65)
0.57 (0.36-0.88)
1001–3000 mg
47
31 (66)
0.19 (0.07-0.49)
47
19 (40)
0.23 (0.06-0.73)
47
38 (81)
0.25 (0.10-0.55)
Significant odds ratio in boldface. CI: confidence interval; FCM: ferric carboxymaltose; N: total number of subjects; n: number of subjects achieving the endpoint; OR: odds ratio. Only patients who had transferrin saturation <20% before treatment were considered for this endpoint. Therefore, all data presented for this endpoint only considers those subjects with iron deficiency. Reference group: cumulative iron dose of 500 mg.
